Here are the 424B prospectus supplements from Harvard Bioscience Inc (HBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HBIO filings page.
Harvard Bioscience, Inc. is registering up to 9,500,000 shares of common stock for resale by existing securityholders. The amount includes up to 2,000,000 shares issuable from warrants with a $0.50 exercise price and up to 7,500,000 shares issuable upon conversion of a $7.5 million Term C Loan at $1.00 per share.
The company is not selling shares in this offering and will not receive proceeds from selling securityholders’ sales, other than up to $1.0 million if all warrants are exercised for cash. Shares outstanding were 44,719,894 as of December 31, 2025, and would be 54,219,894 assuming full warrant exercise and loan conversion. Each selling holder is subject to a 19.99% beneficial ownership cap on exercises and conversions.